Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price reached a new 52-week low on Friday . The company traded as low as C$0.08 and last traded at C$0.08, with a volume of 300926 shares changing hands. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The firm has a market cap of C$15.08 million, a PE ratio of -2.96 and a beta of 0.25. The company has a quick ratio of 0.48, a current ratio of 1.54 and a debt-to-equity ratio of -99.52. The stock has a 50 day moving average price of C$0.09 and a two-hundred day moving average price of C$0.09.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
See Also
- Five stocks we like better than Hemostemix
- MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon
- How JPMorgan’s $8,000 Gold Call Will Leave Most Retirement Accounts Behind
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
